David S Han MD

Family Medicine•Glendale, CA

Shalom Medical Corporation

Join to View Full Profile

1901 Broadview DrGlendale, CA 91208
Phone+1 818-246-3306
Fax+1 818-246-3333

Summary

Dr. David Han is a family physician in Glendale, CA and is affiliated with multiple hospitals in the area, including Adventist Health Glendale, Glendale Memorial Hospital and Health Center, and USC Verdugo Hills Hospital. He received his medical degree from St. George's University School of Medicine and has been in practice 16 years. He also speaks multiple languages, including Korean.

Education & Training

Adventist Health GlendaleResidency, Family Medicine, 2003 - 2006
St. George's University School of MedicineClass of 2003

Certifications & Licensure

CA State Medical License 2005 - 2026
American Board of Family Medicine Family Medicine

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2011-2014

Clinical Trials

Single-Dose Pharmacokinetics (PK) Study of Novel Neurogenic Compound NSI-189 Start of enrollment: 2011 Feb 01
Completed
Phase 1
A Single and Multiple Dose Study to Assess Blood and Urine Drug Levels of Fostamatinib in Healthy Japanese Subjects Start of enrollment: 2012 Jun 01
Completed
Phase 1
A Two-part Multiple Dose Study to Assess the Safety and Effects of AZD3293 in Healthy Elderly and Alzheimer's Patients Start of enrollment: 2013 Mar 01
Completed
Phase 1
AZD6423 SAD/MAD Study in Healthy Volunteers Start of enrollment: 2013 Sep 01
Completed
Phase 1
A Study to Access Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD) of Orally Administered GCC-4401C in Healthy Volunteers Start of enrollment: 2013 Aug 01
Completed
Phase 1
SAD/MAD Study to Assess Safety, Tolerability, PK & PD of MEDI1814 in Subjects With Mild-Moderate Alzheimer's Disease. Start of enrollment: 2014 Feb 04
Completed
Phase 1
Safety, Tolerability, and Pharmacokinetics of Single Doses of APN1125 in Healthy Normal Subjects Start of enrollment: 2014 Dec 01
Completed
Phase 1
A Phase I, Safety Tolerability and Pharmacokinetics of AZD4831 to Treat Cardiovascular Disease Start of enrollment: 2017 May 15
Completed
Phase 1
A Study to Assess the Safety and Pharmacokinetics of Verinurad and Allopurinol in Asian and Chinese Subjects Start of enrollment: 2019 Jan 16
Completed
Phase 1
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD6615 in Healthy Subjects Start of enrollment: 2019 Jul 24
Terminated
Phase 1
A Study to Evaluate the Pharmacokinetics,Safety and Tolerability of Y-2 Sublingual Tablet in Healthy Adult Subjects Start of enrollment: 2023 Sep 06
Completed
Phase 1
A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects Start of enrollment: 2019 Oct 28
Completed
Phase 1
To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD8233 After Multiple Dose Administration in Subjects With Dyslipidemia Start of enrollment: 2019 Nov 21
Completed
Phase 1
A Study to Evaluate the Safety and Pharmacokinetics With MEDI8367 Administered in Healthy Subjects, and in Subjects With Chronic Kidney Disease Start of enrollment: 2020 Jul 22
Completed
Phase 1
A Trial to Evaluate the Safety Tolerability and Pharmacokinetics of B1344 by Subcutaneous Injection in Healthy Subjects Start of enrollment: 2022 Aug 30
Recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

8 citations
Evaluation of a stabilized RSV pre-fusion F mRNA vaccine: Preclinical studies and Phase 1 clinical testing in healthy adults.
Jesse Nussbaum, Xin Cao, Radha A Railkar, Jeffrey R Sachs, Daniel S Spellman
Vaccine. 2023-10-20
2 citations
Single- and Multiple-dose Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP1128, a Novel Peroxisome Proliferator-activated Receptor δ Modulator, in H...
Yuta Taniuchi, J W Olivier van Till, Tomasz Wojtkowski, Junko Toyoshima, Akira Koibuchi
Clinical Pharmacology in Drug Development. 2023-08-01
9 citations
AZD8233 antisense oligonucleotide targeting PCSK9 does not prolong QT interval.
Dinko Rekić, Ivan Azarov, Jane Knöchel, Victor Sokolov, Catarina Nilsson
British Journal of Clinical Pharmacology. 2022-11-01

Professional Memberships

American Academy of Family Physicians - AAFP
Member

Other Languages

Korean